Balakrishnan, 2013 - Google Patents

Alzheimer's disease: Amyloid oligomers, therapeutic agents, their target and mode of action

Balakrishnan, 2013

View PDF
Document ID
13299684451509063847
Author
Balakrishnan K
Publication year

External Links

Snippet

ALZHEIMER’S DISEASE: AMYLOID OLIGOMERS, THERAPEUTIC AGENTS, THEIR TARGETS, AND MODE OF ACTION KARTHIKEYAN BALAKRISHNAN Page 1 AUS DER KLINIK FÜR NEUROLOGIE GESCHÄFTSFÜHRENDER DIREKTOR: PROF. DR. MED. DR. HCWOLFGANG H …
Continue reading at core.ac.uk (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Similar Documents

Publication Publication Date Title
Ono Alzheimer's disease as oligomeropathy
LaFontaine et al. Focus: the aging brain: amyloid-beta Alzheimer targets—protein processing, lipid rafts, and amyloid-beta pores
Soto Unfolding the role of protein misfolding in neurodegenerative diseases
Bayer Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?
Estrada et al. Disrupting β-amyloid aggregation for Alzheimer disease treatment
Finder et al. Amyloid-β aggregation
Larson et al. Soluble Aβ oligomer production and toxicity
Teplow Structural and kinetic features of amyloid β-protein fibrillogenesis
Penke et al. Key peptides and proteins in Alzheimer’s disease
Kovacech et al. Tau truncation is a productive posttranslational modification of neurofibrillary degeneration in Alzheimer's disease
Gunther et al. β-amyloid oligomers and cellular prion protein in Alzheimer’s disease
Kawahara Neurotoxicity of β-amyloid protein: oligomerization, channel formation and calcium dyshomeostasis
US20090035295A1 (en) Screening Method, Process for Purifying of Non-Diffusible A-Beta Oligomers, Selective Antibodies Against Said Non-Diffusible a-Beta Oligomers and a Process for Manufacturing of Said Antibodies
Antonios et al. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
Kuhn et al. Is the p3 peptide (Aβ17-40, Aβ17-42) relevant to the pathology of Alzheimer’s disease?
Mohamed et al. Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide
Walsh et al. The many faces of Aβ: structures and activity
Beyreuther et al. Neurodegenerative disorders: loss of function through gain of function
Balakrishnan Alzheimer’s disease: Amyloid oligomers, therapeutic agents, their target and mode of action
Bhaskar et al. The role of Aβ and tau oligomers in the pathogenesis of Alzheimer’s disease
Ziani-Cherif et al. Gamma-secretase as a pharmacological target in Alzheimer disease research: when, why and how?
JP4937143B2 (en) Method for detecting autoantibodies having specificity for non-diffusible globular Aβ (X-38..43) oligomeric structural epitopes
Urbanc Perplexity of amyloid β-protein oligomer formation: Relevance to Alzheimer’s disease
Ryan et al. The Role of Aβ in Alzheimer's Disease
Rother Impact of amyloid-β reduction on secondary pathological changes in transgenic mouse lines modelling Alzheimer-like pathology